AccScience Publishing / IMO / Online First / DOI: 10.36922/IMO026300055
Cite this article
6
Download
50
Views
Related Info Links
More by Authors Links
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

Integrated machine learning, molecular docking and ADMET analysis for computational prioritization of S1PR1-targeting drug candidates

Akshata P. Pauskar1 ,  Elamathi Natarajan1*
Show Less
1 Department of Bioinformatics, AI, and Machine Learning, Biotecnika Info Labs Pvt Ltd, Bangalore, Karnataka , India
Received: 20 July 2026 | Revised: 7 October 2026 | Accepted: 15 October 2026 | Published online: 17 November 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

Sphingosine-1-phosphate receptor 1 (S1PR1) is a G protein-coupled receptor involved in immune-cell trafficking and has attracted considerable interest as a pharmacological target. The availability of structurally characterized ligand-bound S1PR1 provides an opportunity to combine ligand-based machine learning with structure-based screening to identify additional compounds with potential S1PR1 binding activity. This study aimed to develop and evaluate an integrated computational workflow to identify and prioritize compounds predicted to interact with S1PR1 from an external drug library. Specifically, we investigated whether molecular fingerprints and physicochemical descriptors could reliably predict S1PR1 activity and whether sequential machine-learning screening, drug-likeness filtering, molecular docking, interaction analysis, and absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction could prioritize candidates for further investigation. A curated ChEMBL dataset containing 3,300 unique compounds was used to develop random forest, extreme gradient boosting (XGBoost), logistic regression, and support vector machine models using scaffold-separated training and independent test sets. Random forest and XGBoost demonstrated strong predictive discrimination, with independent-test area under the receiver operating characteristic curve values of 0.9198 and 0.9252, respectively. The optimized random forest model was applied to 12,289 DrugBank compounds, of which 277 met the predefined prediction threshold. Subsequent Lipinski filtering retained 56 compounds for docking, with 54 yielding successful docking results. Integration of predicted activity, docking scores, physicochemical properties, protein–ligand interactions, and ADMET profiles prioritized five compounds: udifitimod, AZD8529, tedizolid phosphate, mocravimod, and BMS-986104. Chemical-space analysis indicated that many DrugBank compounds were structurally distant from the model-development chemical space. Overall, the workflow provides a computational strategy for prioritizing candidates for S1PR1-binding compounds for subsequent experimental evaluation.

Graphical abstract
Keywords
Sphingosine-1-phosphate receptor 1
Machine learning
Virtual screening
Molecular docking
ADMET
Drug discovery
Funding
None.
Conflict of interest
The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.
References
  1. Bravo GÁ, Cedeño RR, Casadevall MP, Ramió-Torrentà L. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives. Cells. 2022;11(13):2058. doi: 10.3390/cells11132058
  2. Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis. Neurotherapeutics. 2017;14(4):859–873. doi: 10.1007/s13311-017-0565-4
  3. Chatzikonstantinou S, Poulidou V, Arnaoutoglou M, et al. Signaling through the S1P−S1PR axis in the gut, the immune and the central nervous system in multiple sclerosis: Implication for pathogenesis and treatment. Cells. 2021;10(11):3217. doi: 10.3390/cells10113217
  4. Brunkhorst R, Vutukuri R, Pfeilschifter W. Fingolimod for the treatment of neurological diseases-state of play and future perspectives. Front Cell Neurosci. 2014;8:283. doi: 10.3389/fncel.2014.00283
  5. Masuda-Kuroki K, Di Nardo A. Sphingosine 1-Phosphate Signaling at the Skin Barrier Interface. Biology. 2022;11(6):809. doi: 10.3390/biology11060809
  6. Hisano Y, Kobayashi N, Yamaguchi A, Nishi T. Mouse SPNS2 Functions as a Sphingosine-1-Phosphate Transporter in Vascular Endothelial Cells. PLoS ONE. 2012;7(6):e38941. doi: 10.1371/journal.pone.0038941
  7. Li J, Huang Y, Zhang Y, et al. S1P/S1PR signaling pathway advancements in autoimmune diseases. Biomol Biomed. 2023;23(6):922–935. doi: 10.17305/bb.2023.9082
  8. Mendelson K, Evans T, Hla T. Sphingosine 1-phosphate signaling. Development. 2014;141(1):5–9. doi: 10.1242/dev.094805
  9. Sassoli C, Pierucci F, Zecchi-Orlandini S, Meacci E. Sphingosine 1-phosphate (S1P)/ S1P receptor signaling and mechanotransduction: Implications for intrinsic tissue repair/regeneration. Int J Mol Sci. 2019;20(22):5545. doi: 10.3390/ijms20225545
  10. Gaidarov I, Komori HK, Stepniak DT, et al. Unique pharmacological properties of etrasimod among S1P receptor modulators. FEBS Open Bio. 2025;15(1):108–121. doi: 10.1002/2211-5463.13907
  11. Chen H, Wang J, Zhang C, et al. Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases. Biomed Pharmacother. 2022;153:113341. doi: 10.1016/j.biopha.2022.113341
  12. Chaudhry B, Cohen J, Conway D. Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis. Neurotherapeutics. 2017;14(4):859-873. doi: 10.1007/s13311-017-0565-4
  13. Roy R, Alotaibi AA, Freedman MS. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis. CNS Drugs. 2021;35(4):385-402. doi: 10.1007/s40263-021-00798-w
  14. Pérez-Jeldres T, Alvarez-Lobos M, Rivera-Nieves J. Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis. Drugs. 2021;81(9):985–1002. doi: 10.1007/s40265-021-01528-8
  15. Park SJ, Im DS. Sphingosine 1-phosphate receptor modulators and drug discovery. Biomol Ther. 2017;25(1):80–90. doi: 10.4062/biomolther.2016.160
  16. Choon XY, Yeo JH, White C, Sharma E, Samaan MA. The Current Sphingosine 1 Phosphate Receptor Modulators in the Management of Ulcerative Colitis. J Clin Med. 2025;14(10):3475.. doi: 10.3390/jcm14103475
  17. Dong J, Wu C, Lu T, et al. Enhancing multifunctional drug screening via artificial intelligence. Digit Discov. 2025;4(8):2012–2024. doi: 10.1039/d5dd00082c
  18. Marinho EM, Batista de Andrade Neto J, Silva J, et al. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease. Microb Pathog. 2020;148:104365. doi: 10.1016/j.micpath.2020.104365
  19. Carpenter KA, Huang X. Machine Learning-based Virtual Screening and Its Applications to Alzheimer’s Drug Discovery: A Review. Curr Pharm Des. 2018;24(28):3347–3358. doi: 10.2174/1381612824666180607124038
  20. Carlsson J, Luttens A. Structure-based virtual screening of vast chemical space as a starting point for drug discovery. Curr Opinion Struct Biol. 2024;87:102829. doi: 10.1016/j.sbi.2024.102829
  21. Roy S, Nagaraj K, Mittal A, Shah FC, Raja K. Artificial Intelligence in Virtual Screening: Transforming Drug Research and Discovery—A Review. J Bio-X Res. 2025:8. doi: 10.34133/jbioxresearch.0041
  22. Verma S, Kumar M, Khare N, Kumar Jha A, Prakash Rai N. Molecular Docking Study on the Effect on Lamin-B1 through Compounds for the Treatment of Multiple Sclerosis. Int J Res Appl Sci Engin Technol. 2021;9(VI):5052–5057. doi: 10.22214/ijraset.2021.36121
  23. Agu PC, Afiukwa CA, Orji OU, et al. Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in disease management. Sci Rep. 2023;13(1):13398. doi: 10.1038/s41598-023-40160-2
  24. Hosseini M, Chen W, Xiao D, Wang C. Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs. Precis Clin Med. 2021;4(1):1–16. doi: 10.1093/pcmedi/pbab001
  25. Alizadeh AA, Jafari B, Dastmalchi S. Drug Repurposing for Identification of S1P1 Agonists with Potential Application in Multiple Sclerosis Using In Silico Drug Design Approaches. Adv Pharm Bull. 2022;13(1):113–122. doi: 10.34172/apb.2023.012
  26. Helmke PS, Ecker GF. Refining Drug-Induced Cholestasis Prediction: An Explainable Consensus Model Integrating Chemical and Biological Fingerprints. J Chem Inf Model. 2025;65(11):5301–5316. doi: 10.1021/acs.jcim.4c02363
  27. Savander S, Curabaz NN, Abbasi AM, Khan A, Saeed K, Tanoli Z. Data-driven strategies for drug repurposing: insights, recommendations, and case studies. Brief Bioinform. 2025;26(6):bbaf625. doi: 10.1093/bib/bbaf625
  28. Burggraaff L, Lenselink EB, Jespers W, et al. Successive statistical and structure-based modeling to identify chemically novel kinase inhibitors. J Chem Inf Model. 2020;60(9):4283–4295. doi: 10.1021/acs.jcim.9b01204
  29. Dey V, Machiraju R, Ning X. Improving Compound Activity Classification via Deep Transfer and Representation Learning. ACS Omega. 2022;7(11):9465–9483. doi: 10.1021/acsomega.1c06805
  30. Turon G, Hlozek J, Woodland JG, Kumar A, Chibale K, Duran-Frigola M. First fully-automated AI/ML virtual screening cascade implemented at a drug discovery centre in Africa. Nat Commun. 2023;14(1):5736. doi: 10.1038/s41467-023-41512-2
  31. Moshawih S, Bu ZH, Goh HP, et al. Consensus holistic virtual screening for drug discovery: a novel machine learning model approach. J Cheminform. 2024;16(1):62. doi: 10.1186/s13321-024-00855-8
  32. Sarkar C, Das B, Rawat VS, et al. Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development. Int J Mol Sci. 2023;24(3):2026. doi: 10.3390/ijms24032026
  33. Bian Y, Kwon JJ, Liu C, Margiotta E, Shekhar M, Gould AE. Target-driven machine learning-enabled virtual screening (TAME-VS) platform for early-stage hit identification. Front Mol Biosci. 2023;10:1163536. doi: 10.3389/fmolb.2023.1163536
  34. Machado LA, Krempser E, Guimarães ACR. A machine learning-based virtual screening for natural compounds capable of inhibiting the HIV-1 integrase. Front Drug Discov. 2022;2:954911. doi: 10.3389/fddsv.2022.954911
  35. Visan AI, Negut I. Integrating Artificial Intelligence for Drug Discovery in the Context of Revolutionizing Drug Delivery. Life. 2024;14(2):233. doi: 10.3390/life14020233
  36. Yin L, Du X, Ma C, Gu H. Virtual Screening of Drug Proteins Based on the Prediction Classification Model of Imbalanced Data Mining. Processes. 2022;10(7):1420. doi: 10.3390/pr10071420
  37. Reddi Durgasree M, Sharma H, Kishen Ajay Kumar V, Jyothi V, Vinay Kumar S. AI-Driven Virtual Screening: Machine Learning-Based Prediction of Molecular Activity and Binding Affinity for Drug Discovery. Int J Hum Comput Intell. 2025;4(6):598–609. doi: 10.5281/zenodo.17082841
  38. Rufibach K. Use of Brier score to assess binary predictions. J Clin Epidemiol. 2010;63(8):938-939. doi: 10.1016/j.jclinepi.2009.11.009
  39. Kant S, Deepika, Roy S. Artificial intelligence in drug discovery and development: transforming challenges into opportunities. Discov Pharm Sci. 2025;1(1):7. doi: 10.1007/s44395-025-00007-3.
  40. Shrestha RL, Tamang A, Chhetri SP, et al. AI-assisted discovery of potent FGFR1 inhibitors via virtual screening and in silico analysis. PLOS ONE. 2025;20(9):e0331837. doi: 10.1371/journal.pone.0331837
  41. Dulsat J, López-Nieto B, Estrada-Tejedor R, Borrell JI. Evaluation of Free Online ADMET Tools for Academic or Small Biotech Environments. Molecules. 2023;28(2):776. doi: 10.3390/molecules28020776
  42. Eswaramoorthy R, Hailekiros H, Kedir F, Endale M. In silico molecular docking, DFT analysis and ADMET studies of carbazole alkaloid and coumarins from roots of Clausena anisata: a potent inhibitor for quorum sensing. Adv Appl Bioinform Chem. 2021;14:13–24. doi: 10.2147/AABC.S290912
  43. Umesh HR, Ramesh KV, Devaraju KS. Molecular docking studies of phytochemicals against trehalose–6–phosphate phosphatases of pathogenic microbes. Beni Suef Univ J Basic Appl Sci. 2020;9(1):5. doi: 10.1186/s43088-019-0028-6
  44. Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. J Chem Inf Model. 2021;61(8):3891–3898. doi: 10.1021/acs.jcim.1c00203
  45. Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–461. doi: 10.1002/jcc.21334
  46. Butt SS, Badshah Y, Shabbir M, Rafiq M. Molecular Docking Using Chimera and AutoDock Vina Software for Nonbioinformaticians. JMIR Bioinform Biotech. 2020;1(1):e14232. doi: 10.2196/14232
  47. Rauf MohdA, Zubair S, Azhar A. Ligand docking and binding site analysis with PyMOL and autodock/vina. Int J Basic Appl Sci. 2015;4(2):168–177. doi: 10.14419/ijbas.v4i2.4123
  48. Azmal M, Paul JK, Prima FS, Talukder OF, Ghosh A, Buday L. An in silico molecular docking and simulation study to identify potential anticancer phytochemicals targeting the RAS signaling pathway. PLOS ONE. 2024;19(9):e0310637. doi: 10.1371/journal.pone.0310637
  49. Agrani W, Perera U, Mudalige H, Perera O. Site-specific docking against HIV-RT protein using AutoDock 4.2.6. GARI Int J Multidiscip Res. 2022;8(3):91-108.
  50. Sharma V, Sharma PC, Kumar V. In Silico Molecular Docking Analysis of Natural Pyridoacridines as Anticancer Agents. Adv Chem. 2016;2016:1–9. doi: 10.1155/2016/5409387
  51. Rudrapal M, Chetia D. Virtual Screening, Molecular Docking and QSAR Studies in Drug Discovery and Development Programme. J Drug Deliv Ther. 2020;10(4):225–233. doi: 10.22270/jddt.v10i4.4218
  52. Pattnaik M, Banerjee P. Virtual Screening of Phytochemicals against NS5 Virus Protein and STAT2 Host Receptor: An In Silico Therapeutic Approach. Int J All Res Educ Sci Methods. 2024;12(9):970-978.
  53. Dunn TB, López-López E, Kim TD, Medina-Franco JL, Miranda-Quintana RA. Exploring activity landscapes with extended similarity: is Tanimoto enough? Mol Inform. 2023;42(7):2300056. doi: 10.1002/minf.202300056.
  54. Fechner N, Jahn A, Hinselmann G, Zell A. Estimation of the applicability domain of kernel-based machine learning models for virtual screening. J Cheminform. 2010;2(1):2. doi: 10.1186/1758-2946-2-2
  55. Dhar TGM, Xiao HY, Xie J, et al. Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials. ACS Med Chem Lett. 2016;7(3):283-288. doi: 10.1021/acsmedchemlett.5b00448
  56. Dertschnig S, Gergely P, Finke J, et al. Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy. Transplant Cell Ther. 2023;29(1):41.e1-41.e9. doi: 10.1016/j.jtct.2022.10.029
Share
Back to top
Innovative Medicines & Omics, Electronic ISSN: 3060-8740 Print ISSN: 3060-8910, Published by AccScience Publishing